|
Patent landscape, scope, and claims: |
United States Patent US8,318,706: Scope, Claims, and Patent Landscape
US8,318,706 is a US drug patent that covers (1) a broad genus of substituted tetracycline-like compounds (Formula I with extensive variable definitions), (2) pharmaceutical compositions containing them, and (3) methods of treating infections (bacterial, viral, parasitic, including malaria). The claim set is structurally centered on a “compound of Formula I” and then recasts the same chemical scope into therapeutic method and composition claims.
Because the variable definitions in claim 1 are extremely permissive, the enforceable scope is primarily driven by (i) what chemical class is actually embodied by “Formula I,” (ii) how “substituted tetracycline compound” is concretely defined in the specification, and (iii) whether the accused compound falls within the exact Markush-style substituent ranges for each variable position.
What does claim 1 actually cover (core scope)?
Claim 1: Genus definition by Formula I with Markush variables
Claim 1 recites:
- A compound of formula I with constraints on substituents at multiple positions:
- X is CR6′R6, or C═CR6′R6
- E is NR7dR7e or OR7f
- R2, R2′, R4′, R4a, R4b each independently = hydrogen or alkyl
- R3, R10, R11, R12 each = hydrogen
- R4 = NR4aR4b
- R5 and R5′ each independently = hydroxyl, hydrogen, or alkyl
- R6 and R6′ each independently = hydrogen, hydroxyl, or alkyl
- R7a, R7b, R7c, R7d, R7e, R7f each independently = hydrogen, alkyl, alkenyl, aryl, or arylalkyl
- Optional ring closure: R7c and R7d can link to form a ring, or R7e and R7f can link to form a ring
- R8 = hydrogen
- R9 = hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, or aminoalkyl, or a pharmaceutically acceptable salt
This is the claim that drives infringement risk for both competitors and partners. It is also the claim most likely to be limited or interpreted through:
- the exact meaning of Formula I substituent positions (as shown/defined in the patent’s drawings/specification), and
- how “substituted tetracycline compound” is operationally characterized by the invention.
Structural interpretation: “tetracycline-like scaffold” + wide substituent latitude
Even with the variable ranges, claim 1 also has tight “fixed” elements:
- R3, R10, R11, R12 are locked to hydrogen
- R8 is locked to hydrogen
- R4 is an amino substituent (NR4aR4b) where R4a/R4b are H or alkyl
Those locked positions tend to be the biggest fault lines between a competitor’s chemical design and literal coverage.
How do claims 2 and 9 narrow the genus (and what do they do legally)?
Claim 2: A specific sub-genus with most positions set to hydrogen
Claim 2 specifies:
- X is CR6′R6
- R4a and R4b are each alkyl
- R2, R2′, R4′, R5, R5′, R6, R6′, and R9 are each hydrogen
This is a meaningful narrowing because it:
- removes variation at multiple positions (many are forced to hydrogen),
- forces a particular oxidation state/unsaturation regime via X = CR6′R6 (as opposed to X being C═CR6′R6),
- and anchors R4 as an alkylated amine at the R4a/R4b level.
Practically, claim 2 is often the “middle ground” fallback claim that can still read on a competitor even if claim 1 is challenged or if a competitor avoids parts of the broader genus.
Claim 9: Another structure claim (Formula-like coverage)
Claim 9 recites:
- A compound of the structure (shown in the patent document)
- or a pharmaceutically acceptable salt thereof
Claim 9 functions as a specific structure claim layered on top of the genus claim. Enforceability usually depends on the exact drawing/structure used, but the legal effect is to provide protection for a particular embodiment even if the genus interpretation becomes contested.
What do the method claims cover (infection scope + malaria) ?
Claim 4: Treating bacterial/viral/parasitic infections
Claim 4 covers:
- A method for treating a bacterial infection, a viral infection, or a parasitic infection in a subject
- administering an effective amount of a compound of claim 1
- “such that said subject is treated”
This is a classic “indication method” claim built on the chemical Markush scope in claim 1.
Claim 5: Malaria subset
Claim 5 narrows claim 4:
- parasitic infection = malaria
Claim 6: Carrier language
Claim 6 specifies:
- compound is administered with a pharmaceutically acceptable carrier
Claim 6 typically broadens formulation/administration routes without changing the core chemical scope.
What do the composition claims cover?
Claim 7: Pharmaceutical composition
Claim 7 covers:
- A pharmaceutical composition comprising
- a therapeutically effective amount of a compound of claim 1
- a pharmaceutically acceptable carrier
Claim 8: Indication language for parasitic/bacterial/viral
Claim 8 specifies that the therapeutically effective amount is effective to treat:
- bacterial infection, viral infection, or parasitic infection
Claim 10: Malaria subset
Claim 10 narrows claim 8:
- parasitic infection = malaria
Scope summary: what a competitor must avoid (literal infringement map)
Below is a practical “design-to-avoid” map anchored on the claim constraints that are explicitly fixed versus variable.
| Variable position group |
Claim 1 constraint type |
Allowed ranges (as written) |
Infringement driver |
| X |
Variable (two options) |
CR6′R6 or C═CR6′R6 |
Determines unsaturation/oxidation state in the X position |
| E |
Variable (two options) |
NR7dR7e or OR7f |
Governs heteroatom type at E position |
| R2, R2′, R4′, R4a, R4b |
Variable (limited) |
H or alkyl |
Limits alkylation degree at key sites |
| R3, R10, R11, R12 |
Fixed |
H only |
Hard boundary for many analogs |
| R4 |
Derived from amine |
NR4aR4b |
Requires amine at R4 with H/alkyl R4a/R4b |
| R5, R5′ |
Variable |
OH, H, or alkyl |
Controls hydroxylation pattern |
| R6, R6′ |
Variable |
H, OH, or alkyl |
Controls substituents at the R6 locus |
| R7a-R7f |
Variable (very wide) |
H, alkyl, alkenyl, aryl, arylalkyl; or ring link across two positions |
Allows large sidechain/aryl substitution patterns |
| R8 |
Fixed |
H only |
Another hard boundary |
| R9 |
Variable (very wide) |
H; alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, aminoalkyl; or salt |
Large freedom, broad coverage risk |
Key legal effect: The claim is a Markush genus with both narrow fixed anchors (R3/R8/R10/R11/R12) and very broad “sidechain freedom” at R7 and R9. Avoidance usually hinges on altering at least one of the fixed anchors or moving outside the required core tetracycline-like arrangement shown in Formula I.
What is the likely patent landscape shape around US8,318,706 (strategy implications)?
Based on the claim language alone, US8,318,706 fits a typical landscape profile for late-stage tetracycline analog families:
- Chemical genus coverage (claim 1) that can cover many analogs and analog-like salts.
- Sub-genus and embodiment claims (claim 2, claim 9) that provide narrower targets for enforcement even if breadth is reduced.
- Indication method coverage (claims 4-6 and 5) that can be used to pursue manufacturing and marketing tied to specific therapeutic uses, including malaria.
- Composition coverage (claims 7-8 and 10) that can reach formulation and dosing products even when specific dosing regimens vary.
Freedom-to-operate logic
Infringement risk for a malaria product built around a tetracycline-like scaffold would generally be assessed against:
- whether the product’s API matches Formula I at the critical fixed positions and required heteroatom patterns, and
- whether marketing/labeling (or real-world use) aligns with claimed infection treatment categories.
If the API fits the genus, “workarounds” based on formulation alone usually fail because the composition claims track the same chemical definition and require only a pharmaceutically acceptable carrier.
What do these claim categories imply for enforcement and licensing?
Enforcement levers
- API-level enforcement: If the API literally matches claim 1 (or a narrower embodiment in claim 2/9), the patentee can target infringement directly through product samples, synthesis routes, and composition analysis.
- Use-level enforcement: If the API does not match the chemical definition, the method claims still generally require chemical match because claim 4 depends on “a compound of claim 1.”
- Formulation-level enforcement: If API matches but formulation differs, claims 7-10 still capture compositions using a therapeutically effective amount with carrier.
Licensing posture
The wide R7/R9 breadth suggests the patentee likely expects:
- incremental analogs within the genus to remain royalty-bearing, and
- malaria-focused licensing if the development program uses the same chemical scaffold class.
Claims-to-landscape matrix (business view)
| Claim group |
Breadth |
Best use in landscape |
Typical boundary against competitors |
| Claim 1 (Formula I) |
Very broad (variable-rich) |
Broad moat for analog families |
Fixed anchors (R3/R8/R10-R12 = H; required R4 = NR4aR4b) and exact Formula I scaffold |
| Claim 2 |
Medium |
Capture analogs with simplified substitution pattern |
Competitors that change the X position or force non-alkyl at R4a/R4b may exit |
| Claim 4-6 |
Indication-tied |
Target marketing tied to infection treatment |
Requires same compound definition; labeling/claims can matter in practice |
| Claim 5 |
Subset |
Malaria-specific enforcement |
Again depends on compound match |
| Claim 7-10 |
Composition + indication |
Product/dosage enforcement |
Requires therapeutically effective amount of claim 1 compound |
Key Takeaways
- US8,318,706 is centered on a Formula I Markush genus (claim 1) of substituted tetracycline-like compounds with extensive sidechain latitude at R7 and R9, while locking key positions to hydrogen (R3, R8, R10-R12).
- The patent adds enforceable layers through:
- a narrower sub-genus (claim 2),
- a specific structure claim (claim 9),
- infection treatment methods for bacterial, viral, parasitic infections (claim 4),
- a malaria subset (claims 5 and 10),
- and pharmaceutical composition claims using pharmaceutically acceptable carriers (claims 7 and 6).
- For landscape and freedom-to-operate, the decisive question is whether an API literally fits Formula I, especially the fixed hydrogen positions and required amine at R4; formulation changes alone usually do not avoid claims 7-10.
FAQs
1) Does US8,318,706 protect only malaria?
No. It protects methods for treating bacterial, viral, and parasitic infections (claim 4), with malaria explicitly called out in claim 5 (and compositions in claim 10). Malaria is a subset, not the only covered indication.
2) Can a competitor avoid the patent by changing the carrier or formulation?
Not by carrier alone. Claim 7 and claim 6 require only a pharmaceutically acceptable carrier for a composition using a therapeutically effective amount of a claim 1 compound.
3) Which claim is the most important for infringement analysis?
Claim 1. Claims 2, 4-6, and 7-10 all depend on the chemical definition of claim 1 (directly or through “compound of claim 1”).
4) Are the substituent ranges broad or narrow?
Broad where the claim defines large variable sets, especially R7a-R7f (H, alkyl, alkenyl, aryl, arylalkyl with optional ring linkage) and R9 (multiple unsaturated and aryl/alcoxy/amino options). Narrow where positions are fixed: R3, R8, R10-R12 = H.
5) What is the practical role of claim 2 and claim 9?
Claim 2 captures a specific configuration with multiple positions forced to hydrogen and a particular X choice. Claim 9 provides protection for a specific drawn structure. Together they strengthen enforceability if breadth of claim 1 is contested and offer narrower targets for product comparisons.
References
- United States Patent US 8,318,706 (claims as provided by user).
More… ↓
⤷ Start Trial
|
